Valneva Reports Positive Topline Results From Phase 3 Trial Of COVID-19 Vaccine Candidate

(RTTNews) - Valneva SE (VALN) said its adjuvanted COVID-19 vaccine candidate, VLA2001, met both co-primary endpoints in phase 3, Cov-Compare trial. VLA2001 showed superiority against AstraZeneca's AZD1222, in terms of geometric mean titer for neutralization antibodies, and non-inferiority in terms of seroconversion rates at two weeks after the second vaccination in adults aged 30 years and older. VLA2001 was generally well tolerated in the trial.

Valneva started rolling submission for initial approval with the UK's Medicines and Healthcare products Regulatory Agency. The company is also preparing to begin rolling submission for conditional approval with the European Medicines Agency.